{"name":"PharmEng Technology","slug":"pharmeng","ticker":"Private","exchange":"Private","domain":"pharmeng.com","description":"PharmEng Technology is a private pharmaceutical engineering and consulting company. They focus on providing innovative solutions for the pharmaceutical industry. Their key products and services include process development, manufacturing, and quality control. As a private company, they do not publicly disclose their market position or revenue.","hq":"Toronto, ON, Canada","founded":0,"employees":"","ceo":"Ross Bhogal","sector":"Pharma Engineering & Consulting","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":85000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Drug X patent cliff ($100M at risk)","drug":"Drug X","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"earnings","headline":"PharmEng Technology Announces Strong Earnings Growth","summary":"PharmEng Technology reported a significant increase in revenue and profitability, driven by growing demand for their services.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"deal","headline":"PharmEng Technology Partners with Leading Pharmaceutical Company","summary":"PharmEng Technology has partnered with a leading pharmaceutical company to provide process development and manufacturing services for their new product.","drugName":"","sentiment":"neutral"}],"realNews":[],"patents":[{"drugName":"Drug X","drugSlug":"generic-x","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Company A","Company B","Company C"],"therapeuticFocus":["Oncology","Cardiovascular"],"financials":null,"yahoo":null}